BIONEWS
Most of Friday's yes votes came from HHS appointees with disclosed peptide industry ties, not career FDA staff.
An FDA advisory panel split from the agency's own scientists on Friday and recommended letting compounding pharmacies manufacture two unapproved peptides, epitalon and semax, according to STAT News. The same panel narrowly voted to reject a third, emideltide. The FDA is not required to follow the panel's recommendation, and acting Commissioner Kyle Diamantas retains authority to overrule career staff before any final rule is published.
The vote triggers a procedural mechanism the standard recap leaves out. Once a substance is added to the federal 503A bulk drug substances list, the roster of ingredients compounding pharmacies are allowed to use, the FDA cannot require compounders to submit safety or efficacy data for products made from that substance. FDA experts told the panel that adding the three peptides would amount to a "dangerous experiment" because physicians would be flying blind on dosing and best practices. An agency official separately told the panel the FDA has no post-listing authority to demand safety or efficacy data from compounders, which is the legal constraint that defines the 503A mechanism.
Compounding pharmacies mix customized doses of drugs, often when an approved version is in short supply or does not yet exist. The two peptides the panel backed are short-chain amino acids whose U.S. popularity has been driven by social media influencers. Neither has cleared the FDA's standard drug-approval process. The panel's Thursday session had already recommended allowing pharmacies to make four other peptides, putting the two-day total at six recommendations to add substances to the 503A list. Friday's narrow rejection of emideltide shows the panel is not rubber-stamping every compound that comes before it, but the broader pattern still points in the same direction.
The composition of the yes votes is the structural story. Most of the panelists who voted to recommend adding epitalon and semax had disclosed ties to the peptide industry and were appointed by the Department of Health and Human Services rather than by career FDA staff. Several argued during deliberations that they were not voting to approve a drug, and therefore did not need to weigh the lack of robust clinical data on the compounds. That framing is the legal trigger for the 503A ratchet: once a substance is on the list, the agency's evidence gate moves from the FDA to the compounder, and it stays there even if the underlying science is later disputed. In practice, any physician who prescribes the resulting compounded peptide, and any patient who takes it, is relying on the compounder's own safety and dosing judgments rather than the FDA's.
Health Secretary Robert F. Kennedy Jr. has publicly prioritized making unapproved peptides more available to Americans, and the two-day meeting crystallized the tension between the Make America Healthy Again movement and mainstream regulatory science. Acting Commissioner Diamantas is a political appointee who can overrule the career staff recommendation, and the administration is required to publish its decision as a proposed rule and accept public comments before finalizing it. The comment window is the concrete lever readers have. It is the only procedural point at which the agency's evidence-based objections can be weighed against the panel's procedural reasoning before the 503A ratchet locks in.
The FDA can also remove a substance from the 503A list after the fact, but the removal process runs through the same rulemaking machinery and is harder to start than to prevent. The agency's scientists have now stated on the record that adding the peptides would be a dangerous experiment. The next move is the comment window, and whether Diamantas or Kennedy let the panel's procedural reasoning, rather than the staff's evidence case, drive the final rule.